Prev1 of 4
Use your ← → (arrow) keys to browse

It's Not Too Late...The world’s best-managed biopharma company is also the most undervalued growth, mega-cap, medical and misunderstood stock in the world… and it’s not too late to get a piece of the pie.

The company’s recent earnings announcement reinforced all this belief, as did Wall Street’s muted reaction to earnings.

The company: Gilead Sciences (NASDAQ: GILD).

Until December 2013, Gilead was known as the dominant, cash-rich and very large market leader in HIV treatments and other products generating more than $10 billion a year in revenue.

That month, the company received approval and began shipping Sovaldi, the first-ever cure for hepatitis C. Less than a year later, Gilead introduced Harvoni, the evolution of Sovaldi. Taken just once a day, Harvoni eliminates the need for other drugs in most hepatitis C patients.

Gilead’s 2014 sales more than doubled to $24 billion. Profits increased even faster. The stock moved with these results, then stalled when Wall Street biopharma analysts saw a competitor from AbbVie (NYSE: ABBV).

Competition? Hardly. The Harvoni/Sovaldi franchise outsold AbbVie’s hepatitis C offer, Viekira Pak, between 10 and 20 to one.

Prev1 of 4
Use your ← → (arrow) keys to browse

Share This